Skip to main content

Table 1 Clinical characteristics of patients with DIPG and mHGG

From: Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics

Patient Age at Diagnosis (years) Sex Primary Tumor Treatment at Diagnosis OS (months) Time to Autopsy (hours)
1 7.7 Male DIPG XRT + bevacizumab, irinotecan 24.4 19
2 2.9 Male DIPG XRT 32.2 17.5
3 4.3 Male DIPG XRT + HDAC inhibitor 11.2 15.5
4 4.4 Male DIPG XRT + HDAC inhibitor 11.5 4.8
5 3.5 Male DIPG XRT + EGFR inhibitor 16.8 5.5
6 23.3 Male DIPG XRT + HDAC inhibitor 13.4 8
7 12.3 Female DIPG XRT + PARP inhibitor, TMZ 11.8 20
8 15.1 Female Bi-thalamic HGG XRT + bevacizumab, TMZ, irinotecan 13.2 8
  1. DIPG diffuse intrinsic pontine glioma, HGG high-grade glioma, TMZ temozolomide, HDAC histone deacetylase, PARP poly ADP ribose polymerase, EGFR epidermal growth factor receptor, OS overall survival, XRT radiotherapy